According to GuruFocus insider data, the recent chief financial officer sells included Chipotle Mexican Grill Inc. (CMG, Financial), Tesla Inc. (TSLA, Financial) and Regeneron Pharmaceuticals Inc. (REGN, Financial).
Chipotle Mexican Grill CFO sold 4,063 shares
CFO Jack Hartung sold 4,063 shares for $915.03 per share on Feb. 14. Since then, the stock has declined 15.97%. Chipotle Mexican Grill has a market cap of $21.35 billion and its shares were traded around $768.93. The company has a price-earnings ratio of 62.16 and a price-sales ratio of 3.90. Over the past 10 years, the restaurant chain had an annual average earnings growth of 6.90%.
Chipotle Mexican Grill announced its fourth-quarter results with revenue of $1.44 billion and gross profit of $276.45 million, while the net income was $72.42 million. The 2019 total revenue was $5.59 billion, a 15% increase from 2018. The gross profit was $1.14 billion, a 25% increase from the year prior. The net income was $350.16 million.
CEO Brian R. Niccol sold 6,256 shares for $899.9 per share on Feb. 12. Since then, the share price has fallen 14.55%. Chief Restaurant Officer Scott Boatwright sold 4,678 shares for $862.12 per share on Feb. 6. The stock has tumbled 10.81% since then.
Tesla CFO sold 150 shares
CFO Zachary Kirkhorn sold 150 shares for $842.22 per share on Feb. 18. Since then, the share price has decreased by 18.19%. Tesla has a market cap of $127.04 billion and its shares were traded around $689. The electric vehicle manufacturer has a price-sales ratio of 5.01.
Tesla announced its fourth-quarter results with revenue of $7.38 billion and gross profit of $1.39 billion, while the net income was $105 million. The 2019 total revenue was $24.58 billion, a 15% increase from 2018. The gross profit was $4.07 billion, a 0.7% increase from the year prior. The net loss was $862 million.
CEO Elon Musk bought 13,037 shares for $767 per share on Feb. 14. Director Lawrence Joseph Ellison also bought 1,250 shares that same day. Since then, the stock has retreated 10.17%. Chief Accounting Officer Vaibhav Taneja sold 1,934 shares for $902.23 per share on Feb. 21. Since then, the shares have fallen 23.63%. Director Antonio J. Gracias sold 77,152 shares for $892.65 per share on Feb. 20. Since then, the stock has slid 22.81%.
Regeneron Pharmaceuticals executive vice president and CFO sold 414 shares
Executive Vice President of Finance and CFO Robert E. Landry sold 414 shares for $452.49 per share on Feb. 26. Since then, the stock has declined 3.61%. Regeneron Pharmaceuticals has a market cap of $47.98 billion and its shares were traded around $436.14. The pharmaceutical company has a price-earnings ratio of 23.61 and a price-sales ratio of 6.36. Over the past five years, Regeneron Pharmaceuticals had an annual average earnings growth of 26.80%.
Regeneron Pharmaceuticals announced its fourth-quarter results with revenue of $2.17 billion and gross profit of $1.95 billion, while the net income was $792 million. The 2018 total revenue was $6.71 billion, a 14% increase from 2017. The gross profit was $6.28 billion, a 15% increase from the year prior. The net income was $2.44 billion.
President and Chief Scientific Officer George Yancopoulos sold 118,123 shares for $420.17 per share on Feb. 24. Since then, the stock has risen 3.8%. Director Michael S. Brown sold 2,000 shares for $419 per share on Feb. 24. Since then, the shares have gained 4.09%. Director Marc Tessier-Lavigne sold 14,279 shares for $400.01 per share on Feb. 13. Since then, the stock has climbed 9.03%.
Disclosure: None.
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
